HIMS241129C38000
- 0.05
- -0.01-16.67%
Hims & Hers Health Newsroom
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Friday; Archer Aviation, MicroStrategy to Advance
Hims & Hers Health Options Spot-On: On November 27th, 113.26K Contracts Were Traded, With 587.36K Open Interest
Spotlight on Hims & Hers Health: Analyzing the Surge in Options Activity
Unusual Options Activity: AAL, COIN and Others Attract Market Bets, AAL V/OI Ratio Reaches 75.0
US stock movement | Hims & Hers Health (HIMS.US) rose over 5%, continuing to set new historical highs.
On Wednesday, Hims & Hers Health (HIMS.US) rose by over 5%, continuing to hit a new all-time high at $32.23.
Hims & Hers Health(HIMS.US) Officer Sells US$3.02 Million in Common Stock
Hims & Hers Health Options Spot-On: On November 26th, 64,572 Contracts Were Traded, With 576.75K Open Interest
U.S. Stock Outlook | All three equity index futures are rising, and the Federal Reserve's minutes from the November mmf policy meeting will be released soon.
On November 26 (Tuesday) pre-market trading, the three major equity index futures of US stocks all rose together.
Express News | White House Announced: Biden-Harris Administration Takes Latest Step to Lower Prescription Drug Costs by Proposing Expanded Coverage of Anti-Obesity Medications for Americans With Medicare and Medicaid
Market Participants Recognise Hims & Hers Health, Inc.'s (NYSE:HIMS) Revenues Pushing Shares 44% Higher
White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs
Top Gap Ups and Downs on Monday: SMCI, ZM, GFI and More
What's Going On With Hims & Hers Health Stock Monday?
Hims & Hers Health Options Spot-On: On November 25th, 203.78K Contracts Were Traded, With 629.63K Open Interest
Hims & Hers Health Trading 22% Higher, WIth Gains Attributed to FDA Nominee
After Trump's nomination of the FDA director, the supplier of "affordable weight loss drugs" Hims & hers surged more than 20%, reaching a historic high.
"Affordable weight loss pharmaceutical" supplier Hims & hers once rose over 20%, reaching $30.57, surpassing the previous intraday record high of $30.44 set on November 13. The reason is that institutions Hunterbrook Media, who benchmark against short sellers Citron, believe that Trump's nomination of Marty Makary as the director of the usa Food and Drug Administration (FDA) could benefit Hims & hers.
Trump's Made His Health Picks. What They Mean for the Sector. -- Barrons.com
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $18
Hims & Hers up 18% Amid Optimism for Compounders With Makary FDA Pick
Unusual Options Activity: SPOT, MOD and Others Attract Market Bets, SPOT V/OI Ratio Reaches 90.4